NCT03088254 - Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

September 20, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

December 4, 2017

Conditions

Dyslipidemia With Hypertension

Interventions

DRUG

Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)

Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks

DRUG

Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)

Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks

DRUG

Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)

Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks

Trial Locations (12)

Chungnam National University Hospital, Daejeon

Chonnam National University Hospital, Gwangju

Seoul National University Bundang Hospital, Gyeonggi-do

Gachon University Gil Medical Center, Incheon

Inje University Haeundae Paik Hospital, Pusan

Ewha Womans University Mokdong Hospital, Seoul

Kangbuk Samsung Hospital, Seoul

Korea University Anam Hospital, Seoul

KyungHee University Hospital at Gangdong, Seoul

Seoul National University Hospital, Seoul

SoonChunHyang University Hospital, Seoul, Seoul

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul